The Experts below are selected from a list of 291579 Experts worldwide ranked by ideXlab platform

Gerald M Reaven - One of the best experts on this subject based on the ideXlab platform.

Johan Arnlov - One of the best experts on this subject based on the ideXlab platform.

Yuan-han Yang - One of the best experts on this subject based on the ideXlab platform.

  • Galantamine Plasma Concentration and cognitive response in Alzheimer's disease.
    PeerJ, 2019
    Co-Authors: Yi-ting Lin, Mei-chuan Chou, Yuan-han Yang
    Abstract:

    Background Galantamine has been approved for the treatment of Alzheimer's disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine Plasma Concentration. The aim of this study was to determine the correlation between galantamine Plasma Concentration and the subsequent cognitive response following treatment in AD patients. Methods AD sufferers who continuously took 8 mg/d galantamine for at least 6 months without previous exposure to other kinds of AChEI such as donepezil, rivastigmine, or memantine were included in this cohort study. The assessments included the Mini Mental Status Examination (MMSE), Clinical Dementia Rating Scale (CDR) and the Cognitive Assessment Screening Instrument (CASI). Each subdomain of the CASI assessment was conducted at baseline and after 6 months of galantamine. The Plasma Concentrations of galantamine were measured by capillary electrophoresis after 6 months of the treatment. Logistic regression was performed to adjust for age, gender, apolipoprotein E e4 genotype status, and baseline score to investigate the association between galantamine Plasma Concentrations and the cognitive response. Results The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months. There was no linear correlation between galantamine Concentration and cognitive response in patients. However, 22 patients were responsive to the treatment in the long-term memory domain. In CASI subset domain, Concentration improved during the 6 months follow up. Conclusions In the limited samples study, galantamine mostly benefitted the cognitive domain of long-term memory. The benefits were not related to the galantamine Plasma Concentration. Objective intra-individual evaluation of therapeutic response should be encouraged.

  • Galantamine Plasma Concentration and cognitive response in Alzheimer’s disease
    PeerJ Inc., 2019
    Co-Authors: Yi-ting Lin, Mei-chuan Chou, Yuan-han Yang
    Abstract:

    Background Galantamine has been approved for the treatment of Alzheimer’s disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine Plasma Concentration. The aim of this study was to determine the correlation between galantamine Plasma Concentration and the subsequent cognitive response following treatment in AD patients. Methods AD sufferers who continuously took 8 mg/d galantamine for at least 6 months without previous exposure to other kinds of AChEI such as donepezil, rivastigmine, or memantine were included in this cohort study. The assessments included the Mini Mental Status Examination (MMSE), Clinical Dementia Rating Scale (CDR) and the Cognitive Assessment Screening Instrument (CASI). Each subdomain of the CASI assessment was conducted at baseline and after 6 months of galantamine. The Plasma Concentrations of galantamine were measured by capillary electrophoresis after 6 months of the treatment. Logistic regression was performed to adjust for age, gender, apolipoprotein E ε4 genotype status, and baseline score to investigate the association between galantamine Plasma Concentrations and the cognitive response. Results The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months. There was no linear correlation between galantamine Concentration and cognitive response in patients. However, 22 patients were responsive to the treatment in the long-term memory domain. In CASI subset domain, Concentration improved during the 6 months follow up. Conclusions In the limited samples study, galantamine mostly benefitted the cognitive domain of long-term memory. The benefits were not related to the galantamine Plasma Concentration. Objective intra-individual evaluation of therapeutic response should be encouraged

Shitij Kapur - One of the best experts on this subject based on the ideXlab platform.

  • olanzapine a systematic review and meta regression of the relationships between dose Plasma Concentration receptor occupancy and response
    Journal of Clinical Psychopharmacology, 2013
    Co-Authors: Delia Bishara, Shitij Kapur, Anna Sparshatt, David Taylor, Olubanke Olofinjana, Maxine X Patel
    Abstract:

    ObjectiveTo conduct a systematic review examining the relationships between olanzapine dose, clinical outcome, dopamine occupancy, and Plasma Concentration; and to evaluate the potential for therapeutic drug monitoring.MethodsA search using Embase, Medline, and Pubmed was conducted; and the literatu

  • a systematic review of aripiprazole dose Plasma Concentration receptor occupancy and response implications for therapeutic drug monitoring
    The Journal of Clinical Psychiatry, 2010
    Co-Authors: Anna Sparshatt, David Taylor, Maxine X Patel, Shitij Kapur
    Abstract:

    Objective To evaluate relationships between aripiprazole dose, Plasma level, pharmacologic activity, and clinical outcome in order to evaluate the potential for therapeutic drug monitoring. Data sources In August 2008, we searched Embase, MEDLINE, and PubMed databases using the keywords aripiprazole, Plasma levels, Plasma Concentration, and therapeutic drug monitoring. Study selection Twenty-one reports were retrieved. Eight studies investigating the relationship between blood Concentrations of aripiprazole and dose, dopamine D(2)/D(3) occupancy, and/or outcome and adverse effects were then selected. Data extraction All data concerning Plasma or serum Concentrations of aripiprazole were included if Concentrations were reported in relation to a dose, dopamine occupancy, or clinical outcome. Those reports solely investigating drug interactions were not included. Data synthesis A strong correlation exists between aripiprazole dose and Plasma Concentration. Positron emission tomography analyses suggest that there are significant relationships between dopamine receptor occupancy and both aripiprazole dose and blood Concentration. Dopamine receptor occupancy appears to reach a plateau at doses above 10 mg, supporting the observation found in dose-response studies that 10 mg/d is the optimal dose for aripiprazole. Conclusions The dose range for aripiprazole is well defined, and it reliably predicts Plasma level, dopamine receptor occupancy, and clinical response. Plasma level variation appears to have minimal impact on clinical response, but it may predict some adverse effects. A putative target Plasma level range of between 150 and 210 ng/mL is suggested. Therapeutic drug monitoring has limited value in the clinical use of aripiprazole, but it may be useful in assuring adherence and optimizing response in individuals.

  • amisulpride dose Plasma Concentration occupancy and response implications for therapeutic drug monitoring
    Acta Psychiatrica Scandinavica, 2009
    Co-Authors: Anna Sparshatt, David Taylor, Maxine X Patel, Shitij Kapur
    Abstract:

    Objective:  To evaluate the relationships between dose, Plasma Concentration, pharmacological activity and clinical outcome to evaluate the appropriateness of therapeutic drug monitoring (TDM) in patients receiving amisulpride. Method:  Literature search of Embase, Medline and PubMed databases. Results:  Amisulpride Plasma Concentration is closely correlated with dose (r2 = 0.96, P < 0.0001), dopamine occupancy, response and with extra-pyramidal symptoms (EPS). Dose is correlated with response, dopamine occupancy and EPS. Optimal clinical response was found at doses of 400–800 mg/day, corresponding to Plasma levels of approximately 200–500 ng/ml. EPS appears to be more reliably predicted by a Plasma level above 320 ng/ml than by a particular dose. Conclusion:  The effects and safety of amisulpride in the treatment of schizophrenia and schizoaffective disorder are predicted by daily dose. The Plasma Concentration threshold for response appears to be approximately 200 ng/ml. EPS are more reliably predicted by Plasma level than by dose. TDM for patients prescribed amisulpride is thus of some clinical value.

Maxine X Patel - One of the best experts on this subject based on the ideXlab platform.

  • olanzapine a systematic review and meta regression of the relationships between dose Plasma Concentration receptor occupancy and response
    Journal of Clinical Psychopharmacology, 2013
    Co-Authors: Delia Bishara, Shitij Kapur, Anna Sparshatt, David Taylor, Olubanke Olofinjana, Maxine X Patel
    Abstract:

    ObjectiveTo conduct a systematic review examining the relationships between olanzapine dose, clinical outcome, dopamine occupancy, and Plasma Concentration; and to evaluate the potential for therapeutic drug monitoring.MethodsA search using Embase, Medline, and Pubmed was conducted; and the literatu

  • a systematic review of aripiprazole dose Plasma Concentration receptor occupancy and response implications for therapeutic drug monitoring
    The Journal of Clinical Psychiatry, 2010
    Co-Authors: Anna Sparshatt, David Taylor, Maxine X Patel, Shitij Kapur
    Abstract:

    Objective To evaluate relationships between aripiprazole dose, Plasma level, pharmacologic activity, and clinical outcome in order to evaluate the potential for therapeutic drug monitoring. Data sources In August 2008, we searched Embase, MEDLINE, and PubMed databases using the keywords aripiprazole, Plasma levels, Plasma Concentration, and therapeutic drug monitoring. Study selection Twenty-one reports were retrieved. Eight studies investigating the relationship between blood Concentrations of aripiprazole and dose, dopamine D(2)/D(3) occupancy, and/or outcome and adverse effects were then selected. Data extraction All data concerning Plasma or serum Concentrations of aripiprazole were included if Concentrations were reported in relation to a dose, dopamine occupancy, or clinical outcome. Those reports solely investigating drug interactions were not included. Data synthesis A strong correlation exists between aripiprazole dose and Plasma Concentration. Positron emission tomography analyses suggest that there are significant relationships between dopamine receptor occupancy and both aripiprazole dose and blood Concentration. Dopamine receptor occupancy appears to reach a plateau at doses above 10 mg, supporting the observation found in dose-response studies that 10 mg/d is the optimal dose for aripiprazole. Conclusions The dose range for aripiprazole is well defined, and it reliably predicts Plasma level, dopamine receptor occupancy, and clinical response. Plasma level variation appears to have minimal impact on clinical response, but it may predict some adverse effects. A putative target Plasma level range of between 150 and 210 ng/mL is suggested. Therapeutic drug monitoring has limited value in the clinical use of aripiprazole, but it may be useful in assuring adherence and optimizing response in individuals.

  • amisulpride dose Plasma Concentration occupancy and response implications for therapeutic drug monitoring
    Acta Psychiatrica Scandinavica, 2009
    Co-Authors: Anna Sparshatt, David Taylor, Maxine X Patel, Shitij Kapur
    Abstract:

    Objective:  To evaluate the relationships between dose, Plasma Concentration, pharmacological activity and clinical outcome to evaluate the appropriateness of therapeutic drug monitoring (TDM) in patients receiving amisulpride. Method:  Literature search of Embase, Medline and PubMed databases. Results:  Amisulpride Plasma Concentration is closely correlated with dose (r2 = 0.96, P < 0.0001), dopamine occupancy, response and with extra-pyramidal symptoms (EPS). Dose is correlated with response, dopamine occupancy and EPS. Optimal clinical response was found at doses of 400–800 mg/day, corresponding to Plasma levels of approximately 200–500 ng/ml. EPS appears to be more reliably predicted by a Plasma level above 320 ng/ml than by a particular dose. Conclusion:  The effects and safety of amisulpride in the treatment of schizophrenia and schizoaffective disorder are predicted by daily dose. The Plasma Concentration threshold for response appears to be approximately 200 ng/ml. EPS are more reliably predicted by Plasma level than by dose. TDM for patients prescribed amisulpride is thus of some clinical value.